Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evaluation, and nitric oxide release studies

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 4061-4067

  Velázquez, Carlos ^a   Rao, P N Praveen ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESTERASE; IBUPROFEN; INDOMETACIN; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; O 2 (ACETYLSALICYLOYLOXYMETHYL) 1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE; O 2 (ACETYLSALICYLOYLOXYMETHYL) 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O 2 [2 [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETOXYMETHYL] 1 (DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE; O 2 [2 [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETOXYMETHYL] 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O 2 [2 [4 (ISOBUTYL)PHENYL]PROPANOYLOXYMETHYL] 1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE; O 2 [2 [4 (ISOBUTYL)PHENYL]PROPANOYLOXYMETHYL] 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; GUINEA PIG; HEART INFARCTION; IN VITRO STUDY; NONHUMAN; PROPHYLAXIS; RAT; STROKE; THROMBOGENESIS; THROMBOSIS; ULCEROGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; AZO COMPOUNDS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESTERS; GUINEA PIGS; IBUPROFEN; INDOMETHACIN; MEMBRANE PROTEINS; NITRIC OXIDE; NITRIC OXIDE DONORS; PRODRUGS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRROLIDINES; RATS; STOMACH ULCER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20444373321     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050211k     Document Type: Article

References (42)

1. Brooks, P. M.; Day, R. O. Nonsteroidal anti-inflammatory drugs-differences and similarities. N. Engl. J. Med. 1991, 324, 1716-1725.
2. Cathella-Lawson, F.; Reilly, M. P.; Kapoor, S. C. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 2001, 345, 1809-1817.
3. Vane, J.; Botting, R. M. Mechanism of action of nonsteroidal antiinflammatory drugs. Am. J. Med. 1998, 104, S2-S8.
4. Rodriguez, L. A. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin. Exp. Rheumatol. 2001, 19, S41-S44.
5. Schoen, R. T.; Vender, R. J. Mechanisms of nonsteroidal antiinflammatory drugs gastric damage. Am. J. Med. 1989, 86, 449-457.
6. Hollander, D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am. J. Med. 1994, 96, 274-281.
7. Rainsford, K. D. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am. J. Med. 1999, 107, S27-S36.
8. Soll, A. H.; Weinstein, W. M.; Kurata, J.; McCarthy, D. Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med. 1991, 114, 307-319.
9. Bjarnason, I.; Hayllar, J.; MacPherson, A. J.; Russell, A. S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104, 1832-1847.
10. Wallace, J. L.; Soldato, P. D. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 2003, 17, 11-20.
11. Sanmuganathan, P. S.; Ghahramani, P.; Jackson, P. R. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001, 85, 265-271.
12. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ (Br. Med. J.) 1994, 308, 81-106.
13. Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Antiinflammatory Drugs. J. Biol. Chem. 1993, 268, 6610-6614.
14. Awtry, E. H.; Loscalzo, J. Cardiovascular drugs: aspirin. Circulation 2000, 101, 1206-1218.
15. Catella-Lawson, F.; Crofford, L. J. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. 2001, 110, S28-S32.
16. Hamberg, M.; Seensson, J.; Samuelson, B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxidases. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 2294-2298.
17. Lee, M.; Cryer, B. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann. Intern. Med. 1994, 120, 184-189.
18. Meade, T. W.; Roderick, P. J.; Brennan, P. J.; Wilkes, H. C.; Kelleher, C. C. Extracraneal bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb. Haemostasis 1992, 68, 1-6.
19. Lanas, A. Nitrovasodilators, low-dose aspirin, other non-steroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 2000, 343, 834-839.
20. Lanza, F. L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other nonsteroidal anti-inflammatory drugs. Scand. J. Gastroenterol. 1989, 24, 24-31.
21. Rainsford, K. D.; Willis, C. Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production. Dig. Dis. Sci. 1982, 27, 624-635.
22. Wallace, J.; McCafferty, D.; Carter, L.; McKnight, W.; Argentieri, D. Tissue selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy. Gastroenterology 1993, 205, 1630-1636.
23. Whittle, B. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981, 80, 94-98.
24. MacNaughton, W. K.; Cirino, G.; Wallace, J. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci. 1989, 45, 1869-1876.
25. Kitagawa, H.; Takeda, F.; Kohei, H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J. Pharmacol. Exp. Ther. 1990, 253, 1133-1137.
26. Wallace, J.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.; Cirino, G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994, 107, 173-179.
27. Wallace, J.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.; Cirino, G. A Diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol 1994, 257, 249-255.
28. Reuter, B.; Cirino, G.; Wallace, J. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci. 1994, 55, PL1-PL8.
29. Cuzzolin, L.; Conforti, A.; Adami, A. Anti-inflammatory potency and gastrointestinal toxicity of a new compound. NO-Naproxen. Pharmacol. Res. 1995, 31, 61-65.
30. Davies, N. M. NO-naproxen vs naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 1997, 11, 69-79.
31. Csont, T.; Ferdinandy, P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol. Ther. 2005, 105, 57-68.
32. Keefer, L. K. Progress toward the clinical application of the nitric oxide-releasing diazeniumdiolates. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 585-607.
33. Tang, X.; Xian, M.; Trikha, M.; Honn, K. V.; Wang, P. G. Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents. Tetrahedron Lett. 2001, 42, 2625-2629.
34. 2N[N(O)NO]-O- functionalization chemistry. J. Org. Chem. 1992, 57, 6134-6138.
35. Hrabie, J. A.; Klose, J. R. New nitric oxide-releasing zwitter-ions derived from polyamines. J. Org. Chem. 1993, 58, 1472-1476.
36. Saavedra, J. E.; Shami, P. J.; Wang, L. Y.; Davies, K. M.; Bohth, M. N.; Citro, M. L.; Keefer, L. K. Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity. J. Med. Chem. 2000, 43, 261-269.
37. Wallace, J.; Reuter, B.; Cirino, G. Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity. J. Gastroenterol. Hepatol. 1994, 9, S40-S44.
38. Rao, P. N. P.; Amini, M.; Li, H.; Habeeb, A.; Knaus, E. E. Design, synthesis, and biological evaluation of 6-substituted-3-(4- methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2003, 46, 4872-4882.
39. Winter, C. A.; Risley, E. A.; Nuss, G. W.; Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-552.
40. Kumar, P.; Knaus, E. E. Synthesis and antiinflammatory activity of N-substituted dihydropyridylacetic acids, esters and amides. Drug Des. Delivery 1987, 2, 145-149.
41. 2-alkyl-1- (pyrrolidin-1-yl)diazen-1-ium-1,2-diolate 4-aryl(heteroaryl)-1,4-dihydro-2,6- dimethyl-3-nitropyridine-5-carboxylates. Drug Dev. Res. 2003, 60, 204-216.
42. Cocco, M. T.; Congiu, C.; Onnis, V.; Morelli, M.; Felipob, V.; Caulia, O. Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg. Med. Chem. 2004, 12, 4169-4177.